Ascendis Pharma A (ASND) Gross Margin (2021 - 2026)
Ascendis Pharma A (ASND) posted Gross Margin of 92.9% for Q1 2026, up 72.79% sequentially from 53.76% in Q4 2025, and up 1025.0% YoY from 8.26% in Q1 2025.
Powered by 
Analysis
Ascendis Pharma A (ASND) Gross Margin (2021 - 2026) Analysis & Trends
Ascendis Pharma A has reported Gross Margin for 6 years, with the latest figure at 92.9% in Q1 2026.
- Quarterly Gross Margin rose 1025.0% year-over-year to 92.9% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 74.51% (up 1221.0% YoY) and the FY2025 annual result came in at 86.82%, down 190.0% from the prior year.
- Gross Margin advanced to 92.9% in Q1 2026 per ASND's latest filing, from 53.76% in the prior quarter.
- Over five years, Gross Margin peaked at 92.9% in Q1 2026 and troughed at 37.81% in Q1 2022.
- A 5-year average of 74.17% and a median of 80.63% in 2024 frame the typical range for Gross Margin.
- The widest YoY moves for Gross Margin: up 7608 bps in 2022, down 6219 bps in 2022.
- Over 5 years, Gross Margin stood at 77.68% in 2022, then slumped by 50 bps to 39.06% in 2023, then jumped by 32 bps to 51.58% in 2024, then climbed by 4 bps to 53.76% in 2025, then jumped by 73 bps to 92.9% in 2026.
- According to Business Quant data, Gross Margin over the past three periods registered 92.9%, 53.76%, and 89.54% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 85.33% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 91.59% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 90.43% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 35.86% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 89.76% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 76.90% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 84.20% |
| 10 | Ascendis Pharma A | 16.39 Bn | 15.45 Bn | 362.22 Mn | 91.85% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 91.85% |
| Mar 31, 2026 | 92.90% |
| Dec 31, 2025 | 90.47% |
| Sep 30, 2025 | 89.54% |
| Jun 30, 2025 | 80.10% |
| Mar 31, 2025 | 82.65% |
| Dec 31, 2024 | 91.94% |
| Sep 30, 2024 | 80.63% |
| Jun 30, 2024 | 68.15% |
| Mar 31, 2024 | 92.11% |
| Dec 31, 2023 | 85.87% |
| Sep 30, 2023 | 84.62% |
| Jun 30, 2023 | 72.72% |
| Mar 31, 2023 | 86.24% |
| Dec 31, 2022 | 77.68% |
| Sep 30, 2022 | 88.93% |
| Jun 30, 2022 | 82.37% |
| Mar 31, 2022 | 37.81% |
| Dec 31, 2021 | 1.60% |
| Sep 30, 2021 | 100.00% |